August 13, 2015

Company: RIBOMIC Inc.
President & CEO: Yoshikazu Nakamura
(Code: 4591, Tokyo Stock Exchange Mothers)
Inquiries: Masayuki Miyazaki, Board Director (Business Administration)
Phone: +81-3-3440-3303

Announcement of Receipt of Notice of Allowance for Product Patent of Anti-Chymase Aptamer (RBM003) by Japanese Patent Office

We are pleased to announce that we have received from the Japanese Patent Office the Notice of Allowance for the product patent of anti-chymase aptamer, a joint application by Ribomic Inc. and Otsuka Pharmaceutical Co., Ltd..
This patent covers the aptamer that inhibits the enzyme activity of chymase, which is assumed to be a causative substance of fibrosis. The patent protects the intellectual property right of RBM003, which is one of the collaborative research projects with Otsuka Pharmaceutical Co., Ltd..
The product patent of RBM003 is already granted in several countries including USA and China.

There is no amendment to our financial estimate for the full fiscal year ending March 31, 2016.